Since the mTOR inhibitor temsirolimus has been approved as a first-line medication for metastatic ccRCC, IMPA2 downregulation may serve as a good biomarker for guiding the use of temsirolimus in the clinical treatment metastatic ccRCC. Here, IMPA2 is linked to nonpapillary renal cell carcinoma.